Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This represents a 66% increase on the prior quarter ended June 30, 2025, with similar gross to net adjustment. Ryoncil is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration for any indication, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).” CEO Dr. Silviu Itescu said: “We are very pleased with the adoption of Ryoncil(R) to date and with reimbursement by both commercial and government payers. We expect adoption to be further enhanced following the permanent J-Code assigned by Centers for Medicare and Medicaid Services which became active October 1.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services
- Mesoblast’s U.S. Origin Designation Shields Products from Tariffs
- Largest borrow rate increases among liquid names
- Buy Rating for Mesoblast Driven by Strong Ryoncil Launch and Strategic Financial Moves
- Mesoblast’s Earnings Call Highlights Growth and Challenges